



Eleison Pharmaceuticals Announces the Appointment of Howard Hochster, MD, to its Science Advisory Board

Princeton, NJ, January 17, 2011 -- Eleison Pharmaceuticals, Inc., a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, has announced the appointment of Dr. Howard Hochster to the company's Science Advisory Board (SAB). Dr. Hochster is Professor of Medicine in medical oncology, Medical Director of Gastrointestinal Oncology, and Associate Director of Clinical Research at Yale Cancer Center.

"Dr. Hochster reviewed previous glufosfamide data, recognized the drug's potential, designed our pivotal study and is our Principal Investigator. We then received an FDA Letter Agreement in response to our SPA request. We are fortunate to have his leadership for glufosfamide, and his Advisory help in other programs" said Forrest Anthony, MD, Chief Medical Officer and President of Eleison Pharmaceuticals.

Dr. Hochster commented, "Glufosfamide has activity in metabolically active GI tumors, and may have utility in both pancreatic and colorectal cancer in the future. I am very pleased to be working with Eleison in the clinical development of this important new drug candidate."

About Dr. Howard S. Hochster:

Dr. Hochster's research focuses on new treatments for GI cancer. He led national, pivotal clinical trials in the use of Bevacizumab and Cetuximab in colorectal cancer, and maintenance Rituximab for the treatment of low-grade lymphoma. Joining Yale Cancer Center in May 2010, he previously was Professor of Medicine at New York University School of Medicine and Director of their Gastrointestinal Cancer Program. He served as the Principal Investigator for the Eastern Cooperative Oncology Group (ECOG) at NYU for the last 16 years. Dr. Hochster is a fellow of the American College of Physicians and a member of the American Society for Internal Medicine, American Society for Clinical Oncology (ASCO), and American Association for Cancer Research. He was President of the New York Cancer Society from 2004-2006. He is active in numerous charitable efforts, including director of the Chemotherapy Foundation and a scientific advisor to the Israel Cancer Research Foundation. Dr. Hochster is a board member of Team Continuum, which raises funds for assistance to cancer patients through marathons and triathlons. Dr. Hochster graduated from the Yale College with BS and MS degrees in chemistry and an MD from Yale School of Medicine. He completed a residency at Bellevue Hospital and his fellowship in medical oncology and hematology at NYU Medical Center. He was then awarded a Fulbright Fellowship to work at the Jules Bordet Cancer Institute in Brussels, Belgium, studying clinical pharmacology and early clinical drug development.

About Eleison Pharmaceuticals:

Eleison's mission is to acquire, develop, and commercialize clinical stage drug candidates for "orphan" indications, providing new hope for patients with rare life-threatening diseases. The Company plans to begin a phase III clinical study of its lead drug candidate, glufosfamide, for pancreatic cancer in mid-2011. Founded in 2008 and headquartered in Princeton, NJ, Eleison is in discussions to acquire other promising programs for rare cancers.

Forward Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Eleison's product candidates, their uses and potential benefits and clinical trial results and plans. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Eleison's ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Eleison does not intend to update any forward-looking statement made in this news release.

SOURCE: Eleison Pharmaceuticals, Inc.

CONTACT: Eleison Pharmaceuticals, Inc.
Corporate Communications
103 Carnegie Center, Suite 300
Princeton, NJ 08504
215-416-7620
info@eleison-pharma.com